Responses
Regular and young investigator award abstracts
Clinical trials in progress
411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients
Compose a Response to This Article
Other responses
No responses have been published for this article.
